1 / 11

Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Total Knee Replaceme

Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of VTE in Total Knee Replacement Surgery Results of the RECORD 3 Study. Rivaroxaban is a novel, oral, direct Factor Xa inhibitor. Background:. Lassen MR, et al. Presented at ISTH 2007 in Geneva, Switzerland, abstract

taipa
Download Presentation

Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Total Knee Replaceme

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery – Results of the RECORD 3 Study M.R. Lassen, A.G. Turpie, N. Rosencher, L.C. Borris, W. Ageno, J.R. Lieberman, T.J. Bandel, F. Misselwitz Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva, Switzerland.

    2. Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of VTE in Total Knee Replacement Surgery – Results of the RECORD 3 Study Rivaroxaban is a novel, oral, direct Factor Xa inhibitor

    3. Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of VTE in Total Knee Replacement Surgery – Results of the RECORD 3 Study Double-blind trial Randomized 2531 patients undergoing TKR to rivaroxaban 10 mg or enoxaparin 40 mg once daily Enoxaparin was started before surgery, and rivaroxaban 6–8 hours after surgery Both were continued for 10–14 days

    4. Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of VTE in Total Knee Replacement Surgery – Results of the RECORD 3 Study Primary efficacy outcome: Venous thromboembolism (VTE) diagnosed by mandatory venography Symptomatic VTE And all-cause mortality Primary safety outcome: Major bleeding

    7. Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of VTE in Total Knee Replacement Surgery – Results of the RECORD 3 Study 1254 patients were randomized to rivaroxaban 824 were evaluable for primary efficacy outcome 1277 patients were randomized to enoxaparin 878 were evaluable for primary efficacy outcome

    12. Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of VTE in Total Knee Replacement Surgery – Results of the RECORD 3 Study Rivaroxaban was significantly more effective than enoxaparin in the prevention of VTE after TKR in this study Bleeding was similarly low in both groups This study with rivaroxaban is the first demonstration of the effectiveness and safety of a fixed, unmonitored regimen of an oral Factor Xa inhibitor in antithrombotic therapy

More Related